Shinobi Therapeutics
Alan Jacks, MBA, currently serves as the Senior Manager and Business Development Lead at Shinobi Therapeutics, where responsibilities include leading fundraising and business development for innovative cell therapies targeting solid tumors and autoimmune diseases. Previously, Alan held the position of Alliance Program Manager at TriSalus Life Sciences, overseeing strategic partnerships and managing a $10M alliance with MD Anderson Cancer Center. At Takeda, Alan progressed through various roles, ultimately leading global programs for novel cell therapies and managing a department focused on budgeting and operations. Alan's earlier experience includes project development at Boston Cares and serving as President of Montgomery Service Leaders, enhancing selectivity in student admissions at Dickinson College. Alan holds an MBA from Questrom School of Business, Boston University and a B.S. in Neuroscience from Dickinson College.
This person is not in any teams
This person is not in any offices
Shinobi Therapeutics
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.